VIDEO: Axpaxli may disrupt treatment paradigm for retinal vascular diseases
Click Here to Manage Email Alerts
NEW YORK — In this Healio Video Perspective from OSN New York, Sanjay Nayak, MBBS, PhD, of Ocular Therapeutix discusses Axpaxli for the treatment of retinal vascular diseases.
According to Nayak, Axpaxli (axitinib intravitreal implant) is “a single injection, a single completely bioabsorbable hydrogel that provides continuous and consistent inhibition of all VEGF receptors for up to 12 months.”
Nayak said Axpaxli has shown positive data in three studies investigating the therapy as a treatment for wet age-related macular degeneration and diabetic retinopathy. It is currently being investigated in two pivotal phase 3 studies.
“We truly hope to disrupt the treatment paradigm for retinal vascular diseases,” Nayak said.
Collapse
Healio/OSN’s disruptive innovations symposium. Presented at: OSN New York and OSN New York Retina; Nov. 8-10, 2024; New York.
Read more about
Click Here to Manage Email Alerts